ADAMO, BARBARA
 Distribuzione geografica
Continente #
NA - Nord America 1.696
EU - Europa 1.687
AS - Asia 257
Continente sconosciuto - Info sul continente non disponibili 2
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 3.645
Nazione #
US - Stati Uniti d'America 1.692
IE - Irlanda 549
SE - Svezia 515
CN - Cina 217
UA - Ucraina 148
DE - Germania 112
IT - Italia 73
FI - Finlandia 68
GB - Regno Unito 64
FR - Francia 44
BE - Belgio 43
PL - Polonia 35
IN - India 31
AT - Austria 18
RU - Federazione Russa 9
VN - Vietnam 6
CA - Canada 4
EU - Europa 2
NL - Olanda 2
PT - Portogallo 2
AU - Australia 1
CL - Cile 1
CZ - Repubblica Ceca 1
ES - Italia 1
HU - Ungheria 1
IR - Iran 1
LB - Libano 1
LV - Lettonia 1
RO - Romania 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 3.645
Città #
Dublin 548
Chandler 333
Jacksonville 291
Nyköping 282
Ashburn 130
Beijing 106
Ann Arbor 85
Dearborn 81
Cambridge 64
Princeton 64
Medford 61
New York 54
Des Moines 50
Brussels 43
Boardman 40
Warsaw 35
Lancaster 34
Pune 28
Messina 26
Vienna 16
Jinan 15
Wilmington 14
Shenyang 13
Woodbridge 13
Nanjing 11
Nanchang 7
Ningbo 7
San Mateo 7
Washington 7
Dong Ket 6
Grammichele 6
Haikou 6
Hebei 6
Tianjin 6
Guangzhou 5
Hangzhou 5
Taiyuan 5
Helsinki 4
Jiaxing 4
Milan 4
Bremen 3
Catania 3
Clearwater 3
Houston 3
Lanzhou 3
Leawood 3
Reggio Calabria 3
Taizhou 3
Zhengzhou 3
Augusta 2
Brooklyn 2
Changsha 2
Fuzhou 2
Lissone 2
London 2
Monmouth Junction 2
Montréal 2
Norwalk 2
Novokuznetsk 2
Porto 2
Acireale 1
Ardabil 1
Belfast 1
Berlin 1
Brno 1
Budapest 1
Cagliari 1
Cannock 1
Chapel Hill 1
Chicago 1
Delhi 1
Edinburgh 1
Filderstadt 1
Florence 1
Giugliano In Campania 1
Hendon 1
Hillsdale 1
Iasi 1
Istanbul 1
Johannesburg 1
Kemerovo 1
Lappeenranta 1
Montreal 1
Mountain View 1
Mountmellick 1
Mumbai 1
Nanning 1
Portsmouth 1
Pozzo 1
Rockford 1
Rüsselsheim 1
Saint Petersburg 1
Seelze 1
Serio 1
Simi Valley 1
Stephentown 1
Swansea 1
Sydney 1
Wenzhou 1
Windsor 1
Totale 2.611
Nome #
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 92
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 89
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 83
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 83
Hereditary breast/ovarian cancer families: The impact of mutation prediction models on BRCA1/2 mutation screening costs. 80
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications. 78
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 77
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. 75
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 74
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 67
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 66
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 65
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 65
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 64
Tumor Characteristics and Adjuvant treatment in Very Young Women 64
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 63
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 63
SAFETY AND ACTIVITY OF ERLOTINIB (TARCEVA) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC, REFRACTORY NON SMALL CELL LUNG CANCER 62
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 61
Embolia polmonare 61
Breast. La terapia primaria: stato dell'arte 60
Phase II trial ZD1839(IRESSA)second-third line in patients with advanced/metastatic non small cell lung cancer (NSCLC):preliminary results 59
BRCA1 missense variants of uncertain clinical significance in unaffected and breast/ovarian cancer of the sicilian population. 59
A Missense Mutation Associated to Early Onset Breast Cancer in A Sicilian Woman. 58
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 58
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 57
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. 56
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 56
Safety of Zoledronic acid in bone metastatic breast cancer patients: A retrospective analysis. 55
Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Sicilian family. 55
Safety and clinical activity of trastuzumab (TSM) containing therapies in heavily pretreated patients with metastatic breast cancer (MBC): A five-year experience 54
A study of a new germline mutation in BRCA1 gene in two Sicilian families: a founder mutation ? 54
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 53
A rare case of malignant solitary fibrous tumor of the spinal cord 53
Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome? 53
Safety of the combination Capecitabine plus Bevacizumab in the treatment of heavily treated advanced colorectal cancer patients: Our experience. 52
Turbe della nutrizione: anoressia e cachessia. 52
BRCA1 germline mutations in sicilian breast and/or ovarian cancer families and their implications for genetic counseling. 52
null 52
Observational study to evaluate the pattern of trastuzumab (T) use and survival outcomes in HER2-positive (HER2+) early breast cancer (EBC): Regional Southern Italy experience. 52
Neoplasie della testa collo nell’ anziano 51
Analysis of the expression levels of Leptin gene and it’s receptor in Breast Cancer patients. 51
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. 49
Prognostic significance of elevated pretreatment serum CA-125 in patients (pts) with epithelial ovarian cancer (CEO) treated with surgery and platinum/taxane-based chemotherapy. 49
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 49
From Adjuvant to Preventive Breast Cancer Treatment: bridging the gap over troubled waters. 48
Preclinical Development of an Intracranial Triple Negative Breast Cancer (TNBC) Tumor Model: A Pilot Study. 48
Strategia Terapeutica nel Carcinoma Prostatico Ormonorefrattario 47
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 46
Multicenter study in women with infracentimetric HER2 positive breast cancer: The Regional Sicilian experience. 45
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 44
Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels 44
Infra-centimetric HER2 positive Breast Cancer: The Southern Italy Experience. 44
AlphaB-crystallin (aBC) expression in breast cancer brain metastases (BM) and primary breast cancer (pBC) with eventual BM and association with outcome 43
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 negative lymphnodes. 43
Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer(MBC): a five year experience. 42
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 42
SAFETY OF PEGILATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ELDERLY WOMEN (>65 YEARS)WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER 41
Stratifying triple-negative breast cancer: which definition(s) to use? 41
Phosphatidylinositol 3-kinase (PI3K) pathway activation in breast cancer brain metastases. 40
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 39
null 37
Primary Therapy in Breast Cancer: The State of the Art. 37
null 33
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 lymphnodes 31
null 22
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications 20
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 16
Totale 3.674
Categoria #
all - tutte 10.724
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.724


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20197 0 0 0 0 0 0 0 0 1 4 1 1
2019/2020555 82 35 3 20 3 84 75 77 8 84 79 5
2020/2021458 68 4 95 29 21 62 12 38 8 49 41 31
2021/2022470 5 69 7 9 21 3 23 13 8 107 66 139
2022/20231.484 98 146 62 103 96 141 30 86 647 11 47 17
2023/2024352 29 50 21 36 36 136 36 1 7 0 0 0
Totale 3.674